COMMUNIQUÉS West-GlobeNewswire

MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines
05/11/2026
Ghent, Belgium – November 5, 2026, Nov. 05, 2026 (GLOBE NEWSWIRE) -- MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines Collaboration [...]
Science 37 Named 2026 “BioTechnology Innovation of the Year” for its Direct-to-Patient Clinical Trial Delivery Model
05/11/2026
The BioTech Breakthrough Award recognizes Science 37’s Direct-to-Patient Site model for expanding patient access and delivering measurable clinical trial performance nationwide MORRISVILLE, N.C., Nov. 05, 2026 (GLOBE [...]
Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12
05/11/2026
DALLAS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies [...]
SpyGlass Pharma to Participate in Upcoming Investor Conferences
05/11/2026
IRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of the executive management [...]
Ovid Therapeutics to Participate in Upcoming Investor Conferences
05/11/2026
NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today [...]
Novastra Therapeutics Establishes Scientific Advisory Board and Appoints Senior Advisors and Head of Clinical Development
05/11/2026
Experts in immuno-oncology, medical oncology, clinical development, and regulatory affairs to guide and support advancement of OmniAntigen™ Platform (OAP) programs OAP enables systematic immune reprogramming therapy ( [...]
Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update
05/11/2026
- Initiation of Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus Expected in Fourth Quarter of 2026 - - Timeline Reaffirmed for Top Line Results from Phase 2 ADMIRATION Trial of Bosakitug (ATI-045) in Atopic [...]
ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results
05/11/2026
Quarterly net revenues of $290.8 million, an increase of 27.6% year-over-year Pu rified Cortrophin ® Gel net revenues of $138.7 million, an increase of 36.1% year-over-year Quarterly GAAP net income available to common [...]
REPEAT – ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business
05/11/2026
Egetis Therapeutics’ lead asset, EMCITATE ® , is the first and only approved treatment in U.S. and Europe for peripheral thyrotoxicosis associated with MCT8 deficiency, a rare genetic disorder, impacting approximately 1 [...]
Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
05/11/2026
Phase 3 bunionectomy and open-label safety trials of onzotrigine remain on track for initiation with topline results expected in the second half of 2027 Company plans to add oxycodone/acetaminophen (commonly known as [...]
Latigo Biotherapeutics Announces CEO Transition to Support the Company’s Next Phase of Growth
05/11/2026
Todd N. Smith, a seasoned executive with deep experience commercializing pain therapies, appointed as president and chief executive officer to lead Latigo through planned late-stage development and commercialization of [...]
Oxford Brain Diagnostics Wins 2026 CNS Summit Innovation Showcase
05/11/2026
MRI-based CDM technology identified patients with MCI who progressed to dementia three times faster, offering drug developers a new tool for patient selection OXFORD, United Kingdom, Nov. 05, 2026 (GLOBE NEWSWIRE) -- [...]
Agios Reports Third Quarter 2026 Financial Results and Provides Business Update
05/11/2026
Mitapivat (PYRUKYND® and AQVESME®) delivered worldwide net revenues of $55.4 million in third quarter of 2026, more than four times the $12.9 million reported in third quarter of 2025 Strong U.S. demand for AQVESME in [...]
ENOVIS Announces Third Quarter 2026 Results
05/11/2026
Third-quarter sales growth of 2% on a reported basis, 5% organic Third-quarter Reconstructive sales growth of 6% on a reported and organic basis Raising full-year 2026 guidance for adjusted EBITDA and adjusted EPS Board [...]
Privia Health Reports Strong Third Quarter and Year-to-Date 2026 Results
05/11/2026
YTD’26 Net Income of $25.6M, +85.9% from YTD’25 YTD’26 Adjusted EBITDA of $114.7M, +21.9% from YTD’25 Full-Year 2026 Guidance Raised to Above High End for All Key Financial Metrics Expands VBC Footprint with Acquisition [...]
Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update
05/11/2026
- Management conference call at 8:30 a.m. ET today - PURCHASE, N.Y., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat [...]
LifeStance Reports Strong Third Quarter 2026 Financial Results and Raises Full Year Outlook
05/11/2026
SCOTTSDALE, Ariz., Nov. 05, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation’s largest providers of outpatient mental healthcare, today announced financial results for the third [...]
Arcoma AB (publ) offentliggör att Eiffel Investment Group passerat 10 procent av aktierna och rösterna.
05/11/2026
PRESSRELEASE 2026-11-05 Arcoma AB (publ) offentliggör att Eiffel Investment Group passerat 10 procent av aktierna och rösterna. Arcoma AB (publ) ("Arcoma") har mottagit information från Eiffel Investment Group om att de [...]
2026 ASH Oral Presentation | InnoCare Announces Phase III Results of Orelabrutinib in ITP Study Meet Primary Endpoint
05/11/2026
BEIJING, Nov. 05, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that results from [...]

Pages